338 related articles for article (PubMed ID: 29411299)
1. A rare CALR variant mutation and a review of CALR in essential thrombocythemia.
Diep R; Metjian A
J Thromb Thrombolysis; 2018 Apr; 45(3):457-462. PubMed ID: 29411299
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
3. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
4. A rare CALR variant mutation and efficient peginterferon alfa-2a response in a patient with essential thrombocythemia.
Ciftciler R; Balasar O
Cancer Genet; 2023 Jun; 274-275():51-53. PubMed ID: 36972657
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
[TBL] [Abstract][Full Text] [Related]
6. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract][Full Text] [Related]
7. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
Rotunno G; Mannarelli C; Guglielmelli P; Pacilli A; Pancrazzi A; Pieri L; Fanelli T; Bosi A; Vannucchi AM;
Blood; 2014 Mar; 123(10):1552-5. PubMed ID: 24371211
[TBL] [Abstract][Full Text] [Related]
8. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
[TBL] [Abstract][Full Text] [Related]
9. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
[TBL] [Abstract][Full Text] [Related]
10. A Novel Pathogenic CALR Exon 9 Mutation in a Patient with Essential Thrombocythemia.
Lee JS; Kim HY; Kim M; Lee YK
Lab Med; 2020 May; 51(3):306-309. PubMed ID: 31626697
[TBL] [Abstract][Full Text] [Related]
11. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].
Ben Said M; Gandrille S; Fischer AM; Darnige L
Pathol Biol (Paris); 2015 Jun; 63(3):117-21. PubMed ID: 25840625
[TBL] [Abstract][Full Text] [Related]
13. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.
Rumi E; Harutyunyan AS; Pietra D; Milosevic JD; Casetti IC; Bellini M; Them NC; Cavalloni C; Ferretti VV; Milanesi C; Berg T; Sant'Antonio E; Boveri E; Pascutto C; Astori C; Kralovics R; Cazzola M;
Blood; 2014 Apr; 123(15):2416-9. PubMed ID: 24553179
[TBL] [Abstract][Full Text] [Related]
14. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2
Saki N; Shirzad R; Rahim F; Saki Malehi A
Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126
[TBL] [Abstract][Full Text] [Related]
15. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726
[TBL] [Abstract][Full Text] [Related]
16. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
17. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
18. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
[TBL] [Abstract][Full Text] [Related]
19. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
Nangalia J; Massie CE; Baxter EJ; Nice FL; Gundem G; Wedge DC; Avezov E; Li J; Kollmann K; Kent DG; Aziz A; Godfrey AL; Hinton J; Martincorena I; Van Loo P; Jones AV; Guglielmelli P; Tarpey P; Harding HP; Fitzpatrick JD; Goudie CT; Ortmann CA; Loughran SJ; Raine K; Jones DR; Butler AP; Teague JW; O'Meara S; McLaren S; Bianchi M; Silber Y; Dimitropoulou D; Bloxham D; Mudie L; Maddison M; Robinson B; Keohane C; Maclean C; Hill K; Orchard K; Tauro S; Du MQ; Greaves M; Bowen D; Huntly BJP; Harrison CN; Cross NCP; Ron D; Vannucchi AM; Papaemmanuil E; Campbell PJ; Green AR
N Engl J Med; 2013 Dec; 369(25):2391-2405. PubMed ID: 24325359
[TBL] [Abstract][Full Text] [Related]
20. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.
Lim KH; Chen CG; Chang YC; Chiang YH; Kao CW; Wang WT; Chang CY; Huang L; Lin CS; Cheng CC; Cheng HI; Su NW; Lin J; Chang YF; Chang MC; Hsieh RK; Lin HC; Kuo YY
Oncotarget; 2017 May; 8(20):32476-32491. PubMed ID: 28415571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
